newsfilter
← Latest News
GlobeNewswire·

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug's commercial potentialIn September 2025, Sol-Gel announced